多靶点粪便免疫化学检测改善粪便结直肠癌筛查项目:荷兰人群配对设计干预研究
在荷兰人群结直肠癌筛查中,邀请55-75岁符合条件者同时提交FIT与mtFIT样本,阳性者转诊结肠镜。mtFIT对进展期肿瘤的检出率为2.27%,高于FIT的1.21%;微模拟模型预测mtFIT筛查可较现行荷兰筛查项目降低结直肠癌发病率21%、相关死亡率18%。
要点
- mtFIT对进展期肿瘤检出率2.27%(95%CI 2.02-2.54),FIT为1.21%(1.03-1.41)。
- mtFIT对进展期腺瘤检出率1.64%(1.43-1.87),FIT为0.86%(0.72-1.04)。
- 模型预测mtFIT筛查较现行荷兰项目降低结直肠癌发病率21%、死亡率18%。
核心结论
- mtFIT对进展期腺瘤的检出率高于FIT,可能转化为结直肠癌发病率和相关死亡率的长期额外且具有临床意义的降低。
研究设计与样本
- 荷兰人群为基础的配对设计干预研究,邀请55-75岁符合荷兰国家FIT结直肠癌筛查项目资格者同时提交同一排便的FIT和mtFIT样本。
- 2022年3月25日至12月7日邀请35786人,15283人(42.7%)同意,其中13187人(86.3%)提供了两种检测均有效的结果。
- 13187名参与者中男性6637人(50.3%),女性6550人(49.7%)。
- FIT阳性(血红蛋白 cutoff 47 μg/g)或mtFIT阳性(基于决策树算法)者转诊结肠镜。
- 主要结局为mtFIT对比FIT对所有进展期肿瘤的相对检出率;次要结局包括结直肠癌、进展期腺瘤和进展期锯齿状息肉各自的相对检出率,以及基于微模拟模型的长期效果。
主要发现
- mtFIT阳性率9.11%(95%CI 8.62-9.61),进展期肿瘤检出率2.27%(95%CI 2.02-2.54);FIT阳性率4.08%(95%CI 3.75-4.43),检出率1.21%(95%CI 1.03-1.41)。
- 结直肠癌检出率mtFIT 0.20%(95%CI 0.13-0.29) vs FIT 0.17%(95%CI 0.11-0.27)。
- 进展期腺瘤检出率mtFIT 1.64%(95%CI 1.43-1.87) vs FIT 0.86%(95%CI 0.72-1.04)。
- 进展期锯齿状息肉检出率mtFIT 0.43%(95%CI 0.33-0.56) vs FIT 0.17%(95%CI 0.11-0.26)。
- 模型显示,与现行荷兰结直肠癌筛查项目相比,基于mtFIT的筛查可使结直肠癌发病率降低21%、相关死亡率降低18%,成本可行。
临床怎么用
- 原文结论指出,mtFIT对进展期腺瘤的检出率高于FIT,可能转化为结直肠癌筛查项目中额外且具有临床意义的长期发病率和死亡率降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The faecal immunochemical test (FIT) is widely employed for colorectal cancer screening. However, its sensitivity for advanced precursor lesions remains suboptimal. The multitarget FIT (mtFIT), measuring haemoglobin, calprotectin, and serpin family F member 2, has demonstrated enhanced sensitivity for advanced neoplasia, especially advanced adenomas, at equal specificity to FIT. This study aimed to prospectively validate and investigate the clinical utlitity of mtFIT versus FIT in a setting of population-based colorectal cancer screening. METHODS: Individuals aged 55-75 years and who were eligible for the Dutch national FIT-based colorectal cancer screening programme were invited to submit both a FIT and mtFIT sample collected from the same bowel movement. Positive FIT (47 μg/g haemoglobin cutoff) or mtFIT (based on decision-tree algorithm) led to a colonoscopy referral. The primary outcome was the relative detection rate of mtFIT versus FIT for all advanced neoplasia. Secondary outcomes were the relative detection rates of colorectal cancer, advanced adenoma, and advanced serrated polyps individually and the long-term effect of mtFIT-based versus FIT-based programmatic screening on colorectal cancer incidence, mortality, and cost, determined with microsimulation modelling. The study has been registered in ClinicalTrials.gov, NCT05314309, and is complete. FINDINGS: Between March 25 and Dec 7, 2022, 35 786 individuals were invited to participate in the study, of whom 15 283 (42·7%) consented, and 13 187 (86·3%) of 15 283 provided both mtFIT and FIT samples with valid results. Of the 13 187 participants, 6637 (50·3%) were male and 6550 (49·7%) were female. mtFIT showed a 9·11% (95% CI 8·62-9·61) positivity rate and 2·27% (95% CI 2·02-2·54) detection rate for advanced neoplasia, compared with a positivity rate of 4·08% (3·75-4·43) and a detection rate of 1·21% (1·03-1·41) for FIT. Detection rates of mtFIT versus FIT were 0·20% (95% CI 0·13-0·29) versus 0·17% (0·11-0·27) for colorectal cancer; 1·64% (1·43-1·87) versus 0·86% (0·72-1·04) for advanced adenoma, and 0·43% (0·33-0·56) versus 0·17% (0·11-0·26) for advanced serrated polyps. Modelling demonstrated that mtFIT-based screening could reduce colorectal cancer incidence by 21% and associated mortality by 18% compared with the current Dutch colorectal cancer screening programme, at feasible costs. Furthermore, at equal positivity rates, mtFIT outperformed FIT in terms of diagnostic yield. At an equally low positivity rate, mtFIT-based screening was predicted to further decrease colorectal cancer incidence by 5% and associated mortality by 4% compared with FIT-based screening. INTERPRETATION: The higher detection rate of mtFIT for advanced adenoma compared with FIT holds the potential to translate into additional and clinically meaningful long-term colorectal cancer incidence and associated mortality reductions in programmatic colorectal cancer screening. FUNDING: Stand Up to Cancer, Dutch Cancer Society, Dutch Digestive Foundation, and Health~Holland.
引用
- Wisse PHA, de Klaver W, van Wifferen F, et al. The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention study. Lancet Oncol. 2024. PMID: 38346438. doi:10.1016/S1470-2045(23)00651-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。